Evaluation of the efficacy of temsirolimus in patients with a recurrent bladder cancer after first-line chemotherapy. Clinical phase II multicenter.
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Temsirolimus (Primary)
- Indications Bladder cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms VESTOR
- 19 Feb 2017 Status changed from active, no longer recruiting to completed.
- 03 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
- 09 Apr 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01827943).